Showing results (2131-2140 of 2,180) with videos related to
Sort By:
Pageof 218
The New England Journal of Medicine|August 13, 2016
Two Phase 3 Trials of Adalimumab for Hidradenitis SuppurativaAlexa B Kimball, Martin M Okun, David A Williams, et al.Dermatology and Therapy|December 23, 2018
Clinical Goals and Barriers to Effective Psoriasis CareBruce E Strober, Joelle M van der Walt, April W Armstrong, et al.Hepatology (Baltimore, Md.)|October 21, 2015
Costs and consequences: Hepatitis C seroprevalence in the military and its impact on potential screening strategiesDavid M Brett-Major, Kevin D Frick, Jennifer A Malia, et al.Journal of Drugs in Dermatology : JDD|December 2, 2025
Report From the 2024 International Dermatology Outcome Measures (IDEOM) Annual MeetingSarah Romanelli, Gretchen D Ball, Arianna J Zhang, et al.Journal of the American Academy of Dermatology|January 10, 2021
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatmentsJoel M Gelfand, April W Armstrong, Stacie Bell, et al.Journal of the American Academy of Dermatology|September 6, 2020
National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1Joel M Gelfand, April W Armstrong, Stacie Bell, et al.Military Medicine|July 11, 2020
Hepatitis B seroprevalence in the U.S. military and its impact on potential screening strategiesPaul T Scott, Robert L Cohen, David M Brett-Major, et al.Circulation. Cardiovascular Imaging|May 20, 2018
Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled TrialNehal N Mehta, Daniel B Shin, Aditya A Joshi, et al.Journal of Drugs in Dermatology : JDD|December 4, 2024
International Dermatology Outcome Measures (IDEOM): A Report From the 2023 Annual MeetingArianna J Zhang, Gretchen Ball, Melissa P Zundell, et al.Lancet (London, England)|September 21, 2025
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trialsLinda Stein Gold, April W Armstrong, Robert Bissonnette, et al.Pageof 218